Nuclera acquires E Ink unit, creates bioprinter

By The Science Advisory Board staff writers

May 12, 2021 -- Nuclera has acquired E Ink's microfluidics unit, and, together, they have developed a desktop bioprinter that will be commercially available in 2022.

The microfluidics unit will be part of the newly formed U.S. subsidiary of Nuclera. Under the deal, E Ink will contribute intellectual property, equipment, and assistance from scientists and engineers and will be made the largest stakeholder in Nuclera.

Nuclera's desktop bioprinter, which is powered by microfluidic technology. Image courtesy of Nuclera.

The companies have been working together to create a bioprinter since 2018. E Ink's digital microfluidics has been combined with Nuclera's biopolymer synthesis technology to create lab-on-chip technology that allows users to digitally program bioprinting of proteins and genes on a desktop for next-day production.

The company expects to commercialize the product in 2022.

Researchers innovate drug discovery screening techniques
Researchers from around the globe gathered to discuss innovations in laboratory techniques such as phenotypic profiling and flow cytometry for drug discovery...
Digital microfluidic technique connects cells to their environment
A new digital microfluidic technique allows researchers to connect physical cell properties with the molecular makeup of individual cells. This new approach,...
Experts map the future of bioprinting
Bioprinting has rapidly advanced in both techniques and clinical applications, but key challenges still remain for the burgeoning field. A multinational...

Copyright © 2021

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter